Contact:
4008465777
-
About Us
News & Events
-
10-20
Tonghua Dongbao selected as one of top 100 most valuable Mainboard-listed companies
On September 28, Securities Times and Caitong Securities published the Ranking of Listed Companies in China by Value for 2021. Tonghua Dongbao Pharmaceutical Co., Ltd. (Tonghua Dongbao or the Company)...
-
09-06
Tonghua Dongbao taps into new market with its first approved oral hypoglycemic drug
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or “the Company”) received the Pharmaceutical Product Registration Certificate for sitagliptin phosphate tablets issued by the National...
-
08-24
Tonghua Dongbao reports YoY increase of 24.47% in net profit for H1 2021 as profitability continues to improve
On the evening of August 24, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2021 half-year report. In H1 2021...
-
07-14
Tonghua Dongbao announces NMPA acceptance of its NDA application for Insulin Aspart 30 and 50 Injections
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) received the notification of acceptance from the National Medical Products Administration (NMPA) on the NDA application...
-
06-30
Tonghua Dongbao introduces two novel drugs to its endocrine product portfolio
On June 30, 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao, introduced two novel gout (hyperuricemia) drugs - THDB130/THDB131...
-
06-28
Tonghua Dongbao gets the nod for clinical trials on world’s first triple SGLT1/SGLT2/DPP4 inhibitor
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”), received the notice...